glucosamine
AssetAlso called Glucosamine sulphate, Glucosamine sulfate, CS+SG, GLU
Supports cartilage matrix synthesis and maintenance.
- Stage
- Phase 3, no development reported
- Modality
- Small molecule
- Target
- Not known
- 3
- Indications
- 26
- Trials
- 4
- Developers
No development reported since August 2014. Last activity: Trial NCT01893905 completed. clinicaltrials.gov
Indications
3Back pain
Phase 3, Completed, NCT00317655, clinicaltrials.gov, Oct 24, 2026
Knee osteoarthritis
Phase 3, Completed, NCT01893905, clinicaltrials.gov, Oct 24, 2026
Gastrointestinal symptoms
Clinical, no phase, doi.org, Jun 24, 2021
In the full profile
- Owner and partners4
- Trials26
- Evidence for its targets1
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.